DPP-4 inhibitors, widely used to treat type 2 diabetes mellitus, may be beneficial to COVID-19 patients with type 2 diabetes, as they can benefit from anti-inflammatory, anti-proliferative, and anti-fibrotic effects, in addition to glycemic regulation (Smelcerovic et al., 2020). The gene discussed is DPP4; the disease is COVID-19.